Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

• Histologically confirmed adenocarcinoma of the prostate
• Voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care
• Patients, even if surgically sterilized (i.e., status post vasectomy), who agree to practice effective barrier contraception during the entire study treatment period and for 4 months after the last dose of study drug, or
• Agree to completely abstain from intercourse
• Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) must be =\< 2.5 x the upper limit of normal (ULN)
• Total bilirubin =\< 1.5 x ULN
• Estimated creatinine clearance using the Cockcroft-Gault formula must be > 40 mL/minute
• Absolute neutrophil count (ANC) >= 1500 cells/microliter
• Platelet count >= 100,000 cells/microliter
• Testosterone \< 50 ng/dL
• Screening calculated ejection fraction of >= 50% by multiple gated acquisition (MUGA) scan or echocardiogram; metastatic progression on primary androgen-deprivation therapy (medical or surgical castration)

• Progression requiring a change in oncologic therapy defined by any of the following:

  • Radiographic progression: appearance or increase in measurable lesions on cross-sectional imaging or appearance of one or more new lesions on bone scan * Rising PSA (>= 2 ng/ml) which has risen on two occasions >= 1 week apart
  • Clinical progression evidenced by increased pain or other cancer-related symptoms

• Patients should have recovered from prior oncologic therapies to a Common Terminology Criteria (CTC) grade =\< 1 except stable neuropathy or alopecia at National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) grade =\< 2; if rapid clinical progression is documented by imaging, changes in PSA, or symptoms, then study treatment can begin >= 2 weeks from prior therapy; otherwise, the following time periods between prior anti-cancer therapies and study treatment day 1 will apply:

  • >= 3 weeks for prior cytotoxic therapies
  • >= 4 weeks for flutamide or nilutamide
  • >= 6 weeks for bicalutamide
  • >= 6 weeks since bone targeted radiopharmaceutical (e.g. samarium-153, radium-223)
• Gonadotropin-releasing hormone (GnRH) agonists (leuprolide acetate, goserelin, etc.) or antagonists (degarelix, etc.) should be continued in patients without surgically-induced castrate androgen levels
• For chemotherapy naïve castration-resistant prostate cancer who are moderately symptomatic or who have hepatic metastasis: subjects must not be a candidate for docetaxel-based chemotherapy.

Exclusion Criteria:

• History of myocardial infarction, unstable symptomatic ischemic heart disease, ongoing arrhythmias of grade > 2 (NCI CTCAE, version 4), thromboembolic events (e.g., deep vein thrombosis, pulmonary embolism, or symptomatic cerebrovascular events), or any other cardiac condition (e.g. pericardial effusion, restrictive cardiomyopathy) within 6 months prior to first dose of study drug; chronic stable atrial fibrillation on stable anticoagulant therapy is allowed
• New York Heart Association class III or IV heart failure

• Electrocardiogram (ECG) abnormalities of:

  • Q-wave infarction, unless identified 6 or more months prior to screening
  • Corrected QT (QTc) interval > 460 msec
• Patient has received other investigational drugs within 28 days before enrollment
• Diagnosed or treated for another malignancy within 2 years of enrollment, with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, an in situ malignancy
• Known hypersensitivity to compounds related to TAK-700 or to TAK-700 excipients
• Uncontrolled hypertension despite appropriate medical therapy (blood pressure [BP] of greater than 160 mmHg systolic and 90 mmHg diastolic at 2 separate measurements no more than 60 minutes apart during the screening visit); Note: patients may be rescreened after adjustment of antihypertensive medications
• Known active chronic hepatitis B or C, life-threatening illness unrelated to cancer, or any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with participation in this study
• Likely inability to comply with the protocol or cooperate fully with the investigator and site personnel
• Known gastrointestinal (GI) disease or GI procedure that could interfere with the GI absorption or tolerance of TAK-700, including difficulty swallowing tablets
• Prior treatment with >= 3 lines of cytotoxic chemotherapy for metastatic prostate cancer
• Prior treatment with TAK-700